A laboratory-made chain of fifteen amino acids with three decades of animal evidence for faster tendon, muscle, ligament and gut repair, and an almost empty human record: three small reports without control groups and one trial enrolling. No approval anywhere, prohibited in sport, most supply unverified. (Full Review)

Protocol

Standard subcutaneous protocol

200–500 µg once or twice daily

For 4–8 weeks, near the injured site or the abdomen. No protocol is validated.

Oral protocol

250–500 µg daily

Gastrointestinal indications. A rodent-scaled dose is far lower, near 110 µg.

Local and procedural protocols

5–10 mg into the knee joint

Or 10 mg at the bladder wall during cystoscopy. Single supervised procedures.

Time to effect

Symptomatic change

1–2 weeks

Typically described in soft-tissue injury. No controlled timeline exists.

Structural change, if any

4–8 weeks

Phase 2 trial imaging endpoint at 14 days, return to sport at 8 weeks.

Duration of knee-pain relief

Beyond 6 months

Reported in the knee series after a single joint injection.

Benefits

Medium: Accelerated healing of tendon, ligament, muscle and bone injury; protection of the gastrointestinal lining against drug- and alcohol-induced damage

Low: Relief of chronic knee pain after joint injection; symptom relief in interstitial cystitis; modulation of blood vessel function; counteraction of corticosteroid-impaired healing; skin and corneal wound healing

Speculative: Neuroprotection and recovery after nerve or brain injury; counteraction of multi-organ injury from interrupted blood supply; gut–brain axis effects on mood and cognition; extension of healthspan

Contraindications

Active malignancy, remission under 5 years, undiagnosed mass, or unexplained weight loss

Proliferative diabetic retinopathy or other disease driven by abnormal new vessel growth

Anti-doping or workplace substance testing

Pregnancy or breastfeeding

Age under 18

Therapeutic anticoagulation or bleeding disorder (haemophilia, von Willebrand)

Severe hepatic (Child-Pugh C) or renal impairment (eGFR below 30 mL/min/1.73 m²)

Hypersensitivity to a compounded peptide

Key Interactions

Nitric oxide-raising and vasodilating medications (nitroglycerin, sildenafil): additive

Antihypertensive medication (lisinopril, amlodipine): potentially additive

Anticoagulants and antiplatelet agents (warfarin, apixaban, clopidogrel): unpredictable

Antipsychotics and dopaminergic agents (haloperidol, levodopa): interfering

Supplements with additive vasodilatory effect (L-Arginine, L-Citrulline, dietary nitrate)

Supplements with additive bleeding risk (high-dose fish oil, vitamin E, Ginkgo biloba)

Other peptides commonly co-administered (TB-500, GHK-Cu): direction unknown

Corticosteroids (prednisone, triamcinolone): opposing, no restriction

Nonsteroidal anti-inflammatory drugs (ibuprofen, aspirin): protective, no restriction

Alcohol: protective, no restriction

Risk & Side Effects

High: Unverified product identity, purity and sterility; anti-doping sanction and regulatory exposure

Medium: Uncharacterised human safety profile and immunogenicity risk; injection-site reactions and injection-related infection

Low: Blood pressure and vascular effects; gastrointestinal upset, headache and fatigue

Speculative: Promotion of undiagnosed tumors; long-term endocrine and metabolic effects

Monitoring

Marker	Target	Why
hs-CRP	Below 1.0 mg/L	Tracks systemic inflammation
ALT	10–26 U/L (women), 10–30 U/L (men)	Reference point for hepatic tolerance
Creatinine and eGFR	eGFR above 90 mL/min/1.73 m²	Confirms the clearance route
Complete blood count with differential	Haemoglobin 13.5–15.0 g/dL (women), 14.0–16.5 g/dL (men)	Detects injection-related infection
IGF-1	Upper-middle of age-banded range	Growth-signalling context
Fasting insulin	2–5 µIU/mL	Metabolic reference point
Resting blood pressure	105–120 / 65–80 mmHg	Nitric oxide vasodilation can lower blood pressure

Cadence: Home blood pressure daily for 2 weeks; blood tests at 4 weeks and course end; repeat courses add a full panel plus cancer screening every 6–12 months. Injection sites inspected daily.

Qualitative Assessment

Pain during the loaded movement that provoked the injury, scored 0–10 each week
Range of motion at the affected joint, measured the same way each week
Tolerated training load without a next-day symptom flare
Morning stiffness duration in the affected tendon
Sleep continuity, as an indirect indicator that night pain is resolving
Energy and any light-headedness on standing, which would flag a vasodilatory effect

BPC-157 for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment